Green light for generic rival to Nexium

July 15, 2011

Indian company Ranbaxy has been given clearance to launch a generic rival to AstraZeneca’s gastrointestinal drug Nexium in the UK

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Topics

More from across our site

Weekly take: Humans of Bombay’s copyright claim could be a tall story

Online storytelling platform Humans of Bombay isn’t wrong for trying to protect its copyright, but it could have handled its dispute better

Sukanya Sarkar, September 26, 2023

Managing IP Awards 2024: in-house submissions invited

We have started accepting submissions from in-house counsel and teams for the 19th annual Managing IP Awards programme

Chris Adams, September 26, 2023

Counsel fear India's patent reform could spark drug access inequity

Patient groups and generics makers may have to bear the brunt of India’s latest attempt at patent reform

Sukanya Sarkar, September 25, 2023

Five minutes with … Tsuyoshi Sueyoshi, Yuasa and Hara

Each week Managing IP speaks to a different IP lawyer about their life and career

Max Walters, September 25, 2023

Top view design on blue background of Hand shaking which print screen on wooden cube block which connection with human icon for business deal and agreement concept.

Exclusive: Rouse hires M&A expert as new COO

Paolo Tavolato, who will share the role, said private equity support would help the IP consultancy achieve its ambitious M&A plans

Rory O’Neill, September 25, 2023

India’s largest firm poaches Anand & Anand partner to kickstart IP practice

Cyril Amarchand Mangaldas has hired former Anand & Anand partner Swati Sharma and hopes to compete with specialist IP firms

Sukanya Sarkar, September 22, 2023

Documents locked with padlock and chains.

UPC denies member of the public access to pleadings

Rapporteur-Judge András Kupecz ruled that education and training weren’t legitimate reasons for a member of the public to access documents

Rory O’Neill, September 22, 2023

Employer with magnifying glass exploring application papers

Counsel: Fed Circuit design patent case decreases prior art burden

Searches for comparison prior art will be a little easier, but practitioners will have to put more thought into claim construction and design patent titles

Rani Mehta, September 22, 2023

UPC refuses preliminary injunction over earlier opt-out

The Helsinki local division rejected AIM Sport’s request for a preliminary injunction in a dispute with rival Supponor

Rory O’Neill, September 22, 2023

Court of Appeals Federal Circuit Lafayette Park Washington DC

This week on MIP: UPC issues first injunction, Newman ban

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP

Rory O’Neill, September 22, 2023